Trial Profile
An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs Miltefosine (Primary) ; Paromomycin (Primary) ; Sodium stibogluconate; Sodium stibogluconate
- Indications Visceral leishmaniasis
- Focus Therapeutic Use
- 20 Sep 2023 Results (n=265) of a Population pharmacokinetic model analysis using data from this trial published in the Journal of Antimicrobial Chemotherapy
- 27 Sep 2022 Primary endpoint has been met (Definitive Cure) , according to Results published in the Clinical Infectious Diseases
- 27 Sep 2022 Results published in the Clinical Infectious Diseases